CYTEIR Trademark

Trademark Overview


On Thursday, July 11, 2019, a trademark application was filed for CYTEIR with the United States Patent and Trademark Office. The USPTO has given the CYTEIR trademark a serial number of 88982018. The federal status of this trademark filing is REGISTERED as of Tuesday, October 5, 2021. This trademark is owned by Cyteir Therapeutics, Inc.. The CYTEIR trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for treatment of cancer and autoimmune diseases; pharmaceutical preparations for use in oncology, hematology, and immunology; synthetic lethal therapies for inducing destruction of diseased cells with DNA damage for medical treatment purposes

Research and development of medical tests for analyzing synthetic lethality and DNA damage; research and development of synthetic lethal therapies and biomarkers of synthetic lethality; medical laboratory services; medical testing for scientific research purposes in the field of oncology, synthetic lethality, and DNA repair; providing medical and scientific research information in the fields of synthetic lethality, DNA repair, synthetic lethal therapies, oncology, hematology, and immunology; drug discovery services
cyteir

General Information


Serial Number88982018
Word MarkCYTEIR
Filing DateThursday, July 11, 2019
Status700 - REGISTERED
Status DateTuesday, October 5, 2021
Registration Number6512466
Registration DateTuesday, October 5, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 25, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations for treatment of cancer and autoimmune diseases; pharmaceutical preparations for use in oncology, hematology, and immunology; synthetic lethal therapies for inducing destruction of diseased cells with DNA damage for medical treatment purposes
Goods and ServicesResearch and development of medical tests for analyzing synthetic lethality and DNA damage; research and development of synthetic lethal therapies and biomarkers of synthetic lethality; medical laboratory services; medical testing for scientific research purposes in the field of oncology, synthetic lethality, and DNA repair; providing medical and scientific research information in the fields of synthetic lethality, DNA repair, synthetic lethal therapies, oncology, hematology, and immunology; drug discovery services

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 18, 2019
Primary Code005
First Use Anywhere DateSunday, November 1, 2020
First Use In Commerce DateSunday, November 1, 2020

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, July 18, 2019
Primary Code042
First Use Anywhere DateFriday, September 30, 2016
First Use In Commerce DateFriday, September 30, 2016

Trademark Owner History


Party NameCyteir Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressLexington, MA 02421

Party NameCyteir Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLexington, MA 02421

Party NameCyteir Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLexington, MA 02421

Trademark Events


Event DateEvent Description
Tuesday, October 5, 2021REGISTERED-PRINCIPAL REGISTER
Tuesday, August 31, 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Saturday, August 28, 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, June 15, 2021STATEMENT OF USE PROCESSING COMPLETE
Monday, March 1, 2021USE AMENDMENT FILED
Tuesday, June 15, 2021DIVISIONAL PROCESSING COMPLETE
Monday, March 1, 2021DIVISIONAL REQUEST RECEIVED
Monday, June 14, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, March 15, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, March 1, 2021TEAS REQUEST TO DIVIDE RECEIVED
Monday, March 1, 2021TEAS STATEMENT OF USE RECEIVED
Tuesday, September 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 18, 2020SOU EXTENSION 1 GRANTED
Friday, September 18, 2020SOU EXTENSION 1 FILED
Friday, September 18, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, April 21, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 25, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 25, 2020PUBLISHED FOR OPPOSITION
Wednesday, February 5, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, January 17, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, January 2, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, January 2, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 2, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 2, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, November 22, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, November 22, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, September 27, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, September 27, 2019NON-FINAL ACTION E-MAILED
Friday, September 27, 2019NON-FINAL ACTION WRITTEN
Thursday, September 26, 2019ASSIGNED TO EXAMINER
Wednesday, September 25, 2019APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, September 23, 2019ASSIGNED TO LIE
Monday, September 16, 2019TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, July 18, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 15, 2019NEW APPLICATION ENTERED